Brief: MaxCyte Q2 Revenue USD 8.2 Million Vs. IBES Estimate USD 9.53 Million

MaxCyte

06/08/2025 21:05

Overview

MaxCyte Q2 total revenue falls 18% yr/yr, missing analyst expectations

Core business revenue rises 8% yr/yr, but SPL revenue drops significantly

Adjusted EBITDA loss widens, missing analyst expectations, per LSEG data

Outlook

MaxCyte expects SPL Program-related revenue of $5 mln for 2025

Company anticipates ending 2025 with at least $155 mln in cash

MaxCyte forecasts core revenue flat to 10% decline vs 2024

Company cites customer inventory management for lowered 2025 guidance

Result Drivers

CORE BUSINESS GROWTH - Core business revenue increased by 8% in Q2 2025, driven by sales of instruments, consumables, and licenses

SPL REVENUE DECLINE - SPL Program-related revenue fell significantly due to timing variability in milestone payments and royalties

LOWERED GUIDANCE - MaxCyte lowered its 2025 guidance due to customer inventory management and pipeline reprioritization impacting expectations

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$8.20 mln
$9.53 mln (6 Analysts)
Q2 Net Income
-$12.40 mln
Q2 Adjusted EBITDA
Miss
-$13.10 mln
-$8.91 mln (4 Analysts)
Q2 Cash & Investments
$165.20 mln
Q2 Gross Profit
$7 mln
Q2 Operating Expenses
$21.20 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for MaxCyte Inc is $6.50, about 68.3% above its August 5 closing price of $2.06

Press Release: ID:nGNXb1TZ3

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)